It appears to the Securities and Exchange Commission that there is a lack of current and accurate information concerning the securities of Artec, Inc. (“ATKJ”) because of questions regarding the accuracy of assertions by ATKJ and others, on ATKJ's Web site, in ATKJ's press releases, and in public statements to investors concerning, among other things, the testing of ATKJ's Tubercin substance for use in treating cancer patients.
The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above listed company.
Therefore, it is ordered, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the above listed company is suspended for the period from 9:30 a.m. e.s.t. December 23, 2004 through 11:59 p.m. e.s.t., on January 7, 2005.
By the Commission.
Jill M. Peterson,
Assistant Secretary.
[FR Doc. 04-28473 Filed 12-23-04; 11:55 am]
BILLING CODE 8010-01-P